<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MELOXICAM - meloxicam tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">ATTENTION DISPENSER: Accompanying Medication Guide <span class="Underline">must</span> be dispensed with this product.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Prescribing Information</span></p>
<p><span class="Bold">WARNING</span></p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Cardiovascular Risk<ul>
<li>NSAIDs may cause an increased risk of serious cardiovascular thrombotic 
events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may 
increase with duration of use. Patients with cardiovascular disease or risk 
factors for cardiovascular disease may be at greater risk (see <span class="Bold"><a href="#section-"> WARNINGS </a></span>and <span class="Bold"><a href="#section-"> CLINICAL TRIALS</a></span>).</li>
<li>Meloxicam is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the 
setting of coronary artery bypass graft (CABG) surgery (see <a href="#section-"> WARNINGS</a> ).</li>
</ul>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Gastrointestinal Risk<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events 
including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, 
which can be fatal. These events can occur at any time during use and without 
warning symptoms. Elderly patients are at greater risk for serious 
gastrointestinal events (see <span class="Bold"><a href="#section-"> WARNINGS</a></span>).</li></ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Meloxicam, an oxicam derivative, is a member of the enolic acid group of 
nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow Meloxicam 
tablet USP contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam 
is chemically designated as 4-hydroxy-2-methyl-<span class="Italics">N</span>-(5-methyl-2-thiazolyl)-<span class="Italics">2H</span>-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The 
molecular weight is 351.4. Its empirical formula is C<span class="Sub">14</span>H<span class="Sub">13</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span> and it has the following structural 
formula.</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe8480c4-b176-45ae-b4d6-fa59912fe286&amp;name=chemical%20structure.jpg"></p>
<p><a href="http://"></a>Meloxicam is a pastel yellow solid, practically insoluble in 
water, with higher solubility observed in strong acids and bases. It is very 
slightly soluble in methanol. Meloxicam has an apparent partition coefficient 
(log P)app = 0.1 in <span class="Italics">n</span>-octanol/buffer pH 7.4. 
Meloxicam has pKa values of 1.1 and 4.2.</p>
<p>Meloxicam is available as a tablet for oral administration containing 7.5 mg 
or 15 mg meloxicam.</p>
<p>The inactive ingredients in Meloxicam tablets USP include colloidal silicon 
dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline 
cellulose, povidone and sodium citrate dihydrate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits 
anti-inflammatory, analgesic, and antipyretic activities in animal models. The 
mechanism of action of meloxicam, like that of other NSAIDs, may be related to 
prostaglandin synthetase (cyclo-oxygenase) inhibition.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><a href="http://"></a><span class="Italics">Absorption</span></p>
<p>The absolute bioavailability of meloxicam capsules was 89% following a single 
oral dose of 30 mg compared with 30 mg IV bolus injection. Following single 
intravenous doses, dose-proportional pharmacokinetics were shown in the range of 
5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam 
capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C<span class="Sub">max</span> was achieved within four to five hours after a 7.5 mg 
meloxicam tablet was taken under fasted conditions, indicating prolonged drug 
absorption. With multiple dosing, steady state concentrations were reached by 
Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours 
post-dose suggesting biliary recycling.</p>
<a name="ieeed0b48-4f1e-4f72-8abf-127619df4e0d"></a><table width="100%">
<caption><span>Table 1 Single Dose and Steady State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)1 </span></caption>
<thead><tr class="First Last">
<th><br></th>
<th><br></th>
<th>Steady State<br>
</th>
<th><br></th>
<th><br></th>
<th>Single Dose<br>
</th>
<th><br></th>
</tr></thead>
<tbody>
<tr class="First">
<td><span class="Bold">Pharmacokinetic<br>Parameters<br>(%CV)<br></span></td>
<td><span class="Bold">Healthy<br>Male Adults<br>(Fed)<span class="Sup">2</span><br></span></td>
<td><span class="Bold">Elderly<br>Males<br>(Fed)<span class="Sup">2</span><br></span></td>
<td><span class="Bold">Elderly<br>Females<br>(Fed)<span class="Sup">2</span><br></span></td>
<td><br></td>
<td><span class="Bold">Renal<br>Failure<br>(Fasted)<br></span></td>
<td><span class="Bold">Hepatic<br>Insufficiency<br>(Fasted)<br></span></td>
</tr>
<tr>
<td><br></td>
<td><span class="Bold">7.5 mg<span class="Sup">3</span><br>tablets<br></span></td>
<td><span class="Bold">15 mg<br>Capsules<br></span></td>
<td><span class="Bold">15 mg<br>Capsules<br></span></td>
<td><br></td>
<td><span class="Bold">15 mg<br>Capsules<br></span></td>
<td><span class="Bold">15 mg<br>Capsules<br></span></td>
</tr>
<tr>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">18</span><br>
</td>
<td>
<span class="Bold">5</span><br>
</td>
<td>
<span class="Bold">8</span><br>
</td>
<td>
<span class="Bold"></span><br>
</td>
<td>
<span class="Bold">12</span><br>
</td>
<td>
<span class="Bold">12</span><br>
</td>
</tr>
<tr>
<td>C<span class="Sub">max          </span>[ug/mL]<br>
</td>
<td>1.05 (20)<br>
</td>
<td>2.3 (59)<br>
</td>
<td>3.2 (24)<br>
</td>
<td><br></td>
<td>0.59 (36)<br>
</td>
<td>0.84 (29)<br>
</td>
</tr>
<tr>
<td>t<span class="Sub">max            </span>[h]<br>
</td>
<td>4.9 (8)<br>
</td>
<td>5 (12)<br>
</td>
<td>6 (27)<br>
</td>
<td>     <br>
</td>
<td>4 (65)<br>
</td>
<td>10 (87)<br>
</td>
</tr>
<tr>
<td>t<span class="Sub">1</span><span class="Sub">/</span><span class="Sub">2              </span>[h]</td>
<td>20.1 (29)<br>
</td>
<td>21 (34)<br>
</td>
<td>24 (34)<br>
</td>
<td><br></td>
<td>18 (46)<br>
</td>
<td>16 (29)<br>
</td>
</tr>
<tr>
<td>CL/f       [mL/min]<br>
</td>
<td>8.8 (29)<br>
</td>
<td>9.9 (76)<br>
</td>
<td>5.1 (22)<br>
</td>
<td><br></td>
<td>19 (43)<br>
</td>
<td>11 (44)<br>
</td>
</tr>
<tr class="Last">
<td>Vz/f<span class="Sup">4         </span>[L]<span class="Sup"></span>
</td>
<td>14.7 (32)<br>
</td>
<td>15 (42)<br>
</td>
<td>10 (30)<br>
</td>
<td><br></td>
<td>26 (44)<br>
</td>
<td>14 (29)<br>
</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span> The parameter values in the Table are from various studies <br><span class="Sup">2</span> not under high fat conditions<br><span class="Sup">3</span> Meloxicam tablets<br><span class="Sup">4</span> Vz/f =Dose/(AUC•Kel)<br><br><p><a href="http://"></a><span class="Italics">Food and Antacid Effects</span></p>
<p>Administration of meloxicam capsules following a high fat breakfast (75 g of 
fat) resulted in mean peak drug levels (i.e., C<span class="Sub">max</span>) being 
increased by approximately 22% while the extent of absorption (AUC) was 
unchanged. The time to maximum concentration (T<span class="Sub">max</span>) was 
achieved between 5 and 6 hours. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was detected with 
concomitant administration of antacids. Based on these results, meloxicam can be 
administered without regard to timing of meals or concomitant administration of 
antacids.</p>
<p><span class="Italics">Distribution</span></p>
<p>The mean volume of distribution (Vss) of meloxicam is approximately 10 L. 
Meloxicam is ~ 99.4% bound to human plasma proteins (primarily albumin) within 
the therapeutic dose range. The fraction of protein binding is independent of 
drug concentration, over the clinically relevant concentration range, but 
decreases to ~ 99% in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Meloxicam penetration into 
human red blood cells, after oral dosing, is less than 10%. Following a 
radiolabeled dose, over 90% of the radioactivity detected in the plasma was 
present as unchanged meloxicam.</p>
<p>Meloxicam concentrations in synovial fluid, after a single oral dose, range 
from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 
times higher than in plasma, due to the lower albumin content in synovial fluid 
as compared to plasma. The significance of this penetration is unknown.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Meloxicam is almost completely metabolized to four pharmacologically inactive 
metabolites. The major metabolite, 5'-carboxy meloxicam (60% of dose), from 
P-450 mediated metabolism was formed by oxidation of an intermediate metabolite 
5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of 
dose). <span class="Italics">In vitro </span>studies indicate that cytochrome 
P-450 2C9 plays an important role in this metabolic pathway with a minor 
contribution of the CYP 3A4 isozyme. Patients’ peroxidase activity is probably 
responsible for the other two metabolites which account for 16% and 4% of the 
administered dose, respectively.</p>
<p><span class="Italics">Excretion</span></p>
<p>Meloxicam excretion is predominantly in the form of metabolites, and occurs 
to equal extents in the urine and feces. Only traces of the unchanged parent 
compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the 
urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% 
and 13% of the dose were found in urine in the form of meloxicam, and the 
5'-hydroxymethyl and 5'-carboxy metabolites, respectively. There is significant 
biliary and/or enteral secretion of the drug. This was demonstrated when oral 
administration of cholestyramine following a single IV dose of meloxicam 
decreased the AUC of meloxicam by 50%.</p>
<p>The mean elimination half-life (t<span class="Sub">1/2</span>) ranges from 15 
hours to 20 hours. The elimination half-life is constant across dose levels 
indicating linear metabolism within the therapeutic dose range. Plasma clearance 
ranges from 7 to 9 mL/min.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<p class="First"><a href="http://"></a><span class="Italics">Geriatric</span></p>
<p>Elderly males(≥ 65 years of age) exhibited meloxicam plasma concentrations 
and steady state pharmacokinetics similar to young males. Elderly females (≥ 65 
years of age) had a 47% higher AUCss and 32% higher C<span class="Sub">max</span>, 
ss as compared to younger females (≤ 55 years of age) after body weight 
normalization. Despite the increased total concentrations in the elderly 
females, the adverse event profile was comparable for both elderly patient 
populations. A smaller free fraction was found in elderly female patients in 
comparison to elderly male patients.</p>
<p><span class="Italics">Gender</span></p>
<p>Young females exhibited slightly lower plasma concentrations relative to 
young males. After single doses of 7.5 mg meloxicam, the mean elimination 
half-life was 19.5 hours for the female group as compared to 23.4 hours for the 
male group. At steady state, the data were similar (17.9 hours vs. 21.4 hours). 
This pharmacokinetic difference due to gender is likely to be of little clinical 
importance. There was linearity of pharmacokinetics and no appreciable 
difference in the C<span class="Sub">max</span> or T<span class="Sub">max</span> 
across genders.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>Following a single 15 mg dose of meloxicam there was no marked difference in 
plasma concentrations in subjects with mild (Child-Pugh Class I) and moderate 
(Child-Pugh Class II) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to healthy volunteers. Protein 
binding of meloxicam was not affected by <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. No dose 
adjustment is necessary in mild to moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Patients with 
severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class III) have not been adequately 
studied.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>Meloxicam pharmacokinetics have been investigated in subjects with different 
degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Total drug plasma concentrations decreased with 
the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> while free AUC values were similar. Total 
clearance of meloxicam increased in these patients probably due to the increase 
in free fraction leading to an increased metabolic clearance. There is no need 
for dose adjustment in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (CrCL &gt;15 
mL/min). Patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been adequately 
studied. The use of meloxicam in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not 
recommended (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID39">Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></a></span>).</p>
<p><span class="Italics">Hemodialysis</span></p>
<p>Following a single dose of meloxicam, the free Cmax plasma concentrations 
were higher in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> on chronic hemodialysis (1% free 
fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis 
did not lower the total drug concentration in plasma; therefore, additional 
doses are not necessary after hemodialysis. Meloxicam is not dialyzable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> </h2>
<p class="First">The use of meloxicam for the treatment of the signs and symptoms of 
<span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee and hip was evaluated in a 12-week double-blind 
controlled trial. Meloxicam (3.75 mg, 7.5 mg and 15 mg daily) was compared to 
placebo. The four primary endpoints were investigator’s global assessment, 
patient global assessment, patient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> assessment, and total WOMAC score (a 
self-administered questionnaire addressing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, function and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>). 
Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed significant 
improvement in each of these endpoints compared with placebo.</p>
<p>The use of meloxicam for the management of signs and symptoms of 
<span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> was evaluated in six double-blind, active-controlled trials 
outside the U.S. ranging from 4 weeks to 6 months duration. In these trials, the 
efficacy of meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to 
piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the 
efficacy seen in the U.S. trial. </p>
<p>The use of meloxicam for the treatment of the signs and symptoms of 
<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> was evaluated in a 12-week double-blind, controlled 
multinational trial. Meloxicam (7.5 mg, 15 mg and 22.5 mg daily) was compared to 
placebo. The primary endpoint in this study was the ACR20 response rate, a 
composite measure of clinical, laboratory and functional measures of RA 
response. Patients receiving meloxicam 7.5 mg and 15 mg daily showed significant 
improvement in the primary endpoint compared with placebo. No incremental 
benefit was observed with the 22.5 mg dose compared to the 15 mg dose.</p>
<p>Higher doses of meloxicam (22.5 mg and greater) have been associated with an 
increased risk of serious GI events; therefore the daily dose of meloxicam 
should not exceed 15 mg. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a href="http://"></a>Carefully consider the potential benefits and risks of 
meloxicam and other treatment options before deciding to use meloxicam. Use the 
lowest effective dose for the shortest duration consistent with individual 
patient treatment goals (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>).</p>
<p>Meloxicam is indicated for relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> 
and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a href="http://"></a>Meloxicam is contraindicated in patients with known 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to meloxicam.</p>
<p>Meloxicam should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. 
Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported 
in such patients (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, 
<span class="Bold"><a href="#ID41"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></span>, and <span class="Bold"><a href="#ID47">PRECAUTIONS</a></span>, <span class="Bold"><a href="#ID56">Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>).</p>
<p>Meloxicam is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the 
setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<a href="http://"></a>Cardiovascular Thrombotic Events<p class="First"><a href="http://"></a>Clinical trials of several COX-2 selective and nonselective 
NSAIDs of up to three years duration have shown an increased risk of serious 
cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which 
can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for the 
development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID35">Gastrointestinal (GI) Effects - Risk of GI 
Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>).</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the 
treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an 
increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <span class="Bold"><a href="#ID25">CONTRAINDICATIONS</a></span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><p><a href="http://"></a>NSAIDs, including meloxicam can lead to onset of new 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may 
contribute to the increased incidence of CV events. Patients taking thiazides or 
loop diuretics may have impaired response to these therapies when taking NSAIDs. 
NSAIDs, including meloxicam should be used with caution in patients with 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the 
initiation of NSAID treatment and throughout the course of therapy.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><p><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some 
patients taking NSAIDs. Meloxicam should be used with caution in patients with 
<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Gastrointestinal (GI) Effects - Risk of GI Ulceration, 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation<p><a href="http://"></a>NSAIDs, including meloxicam can cause serious 
gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, 
ulceration, and perforation of the stomach, small intestine, or large intestine, 
which can be fatal. These serious adverse events can occur at any time, with or 
without warning symptoms, in patients treated with NSAIDs. Only one in five 
patients, who develop a serious upper GI adverse event on NSAID therapy, is 
symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs, 
occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% 
of patients treated for one year. These trends continue with longer duration of 
use, increasing the likelihood of developing a serious GI event at some time 
during the course of therapy. However, even short-term therapy is not without 
risk.</p>
<p>NSAIDs should be prescribed with extreme caution in those with a prior 
history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a <span class="Italics">prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or gastrointestinal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </span>who use NSAIDs have a greater than 10-fold increased risk for 
developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. 
Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with 
NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer 
duration of NSAID therapy, smoking, use of alcohol, older age, and poor general 
health status. Most spontaneous reports of fatal GI events are in elderly or 
debilitated patients and therefore, special care should be taken in treating 
this population. </p>
<p>To minimize the potential risk for an adverse GI event in patients treated 
with an NSAID, the lowest effective dose should be used for the shortest 
possible duration. Patients and physicians should remain alert for signs and 
symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly 
initiate additional evaluation and treatment if a serious GI adverse event is 
suspected. This should include discontinuation of the NSAID until a serious GI 
adverse event is ruled out. For high-risk patients, alternate therapies that do 
not involve NSAIDs should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs including meloxicam can result in renal 
papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and other renal 
injury. Renal toxicity has also been seen in patients in whom renal 
prostaglandins have a compensatory role in the maintenance of renal perfusion. 
In these patients, administration of a nonsteroidal anti-inflammatory drug may 
cause a dose-dependent reduction in prostaglandin formation and, secondarily, in 
renal blood flow, which may precipitate overt renal decompensation. Patients at 
greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, heart 
failure, liver dysfunction, those taking diuretics and ACE inhibitors, 
angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID 
therapy is usually followed by recovery to the pretreatment state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">No information is available from controlled clinical studies regarding the use 
of meloxicam in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with 
meloxicam is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If 
meloxicam therapy must be initiated, close monitoring of the patient's renal 
function is advisable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDS, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients without 
known prior exposure to meloxicam. Meloxicam should not be given to patients 
with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> 
patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit 
severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see 
<span class="Bold"><a href="#ID25">CONTRAINDICATIONS </a></span>and <span class="Bold"><a href="#ID47">PRECAUTIONS</a></span>, <span class="Bold"><a href="#ID56">Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). Emergency help should be sought in 
cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including meloxicam can cause serious skin adverse events such as 
<span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, Stevens - Johnson syndrome (SJS), and toxic epidermal 
necrolysis (TEN), which can be fatal. These serious events may occur without 
warning. Patients should be informed about the signs and symptoms of serious 
skin manifestations and use of the drug should be discontinued at the first 
appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, meloxicam should be avoided because it 
may cause premature closure of the ductus arteriosus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First"><a href="http://"></a>Meloxicam cannot be expected to substitute for 
corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation 
of corticosteroids may lead to disease exacerbation. Patients on prolonged 
corticosteroid therapy should have their therapy tapered slowly if a decision is 
made to discontinue corticosteroids.</p>
<p>The pharmacological activity of meloxicam in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> 
may diminish the utility of these diagnostic signs in detecting complications of 
presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First"><a href="http://"></a>Borderline elevations of one or more liver tests may occur 
in up to 15% of patients taking NSAIDs including meloxicam. These laboratory 
abnormalities may progress, may remain unchanged, or may be transient with 
continuing therapy. Notable elevations of ALT or AST (approximately three or 
more times the upper limit of normal) have been reported in approximately 1% of 
patients in clinical trials with NSAIDs. In addition, rare cases of severe 
hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, liver 
<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been 
reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom 
an abnormal liver test has occurred, should be evaluated for evidence of the 
development of a more severe hepatic reaction while on therapy with meloxicam. 
If clinical signs and symptoms consistent with liver disease develop, or if 
systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), meloxicam should 
be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First"><a href="http://"></a>Caution should be used when initiating treatment with 
meloxicam in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. It is advisable to 
rehydrate patients first and then start therapy with meloxicam. Caution is also 
recommended in patients with pre-existing kidney disease (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID37">Renal Effects </a></span>and <span class="Bold"><a href="#ID39">Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></a></span>).</p>
<p>The extent to which metabolites may accumulate in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> 
has not been studied with meloxicam. Because some meloxicam metabolites are 
excreted by the kidney, patients with significantly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> 
should be more closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Hematological Effects</h2>
<p class="First"><a href="http://"></a><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, 
including meloxicam. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI 
blood loss, or an incompletely described effect upon erythropoiesis. Patients on 
long-term treatment with NSAIDs, including meloxicam, should have their 
hemoglobin or hematocrit checked if they exhibit any signs or symptoms of 
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Drugs which inhibit the biosynthesis of prostaglandins may interfere to some 
extent with platelet function and vascular responses to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
time in some patients. Unlike aspirin their effect on platelet function is 
quantitatively less, of shorter duration, and reversible. Patients receiving 
meloxicam who may be adversely affected by alterations in platelet function, 
such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants 
should be carefully monitored. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in 
patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe 
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, 
between aspirin and other NSAIDs has been reported in such aspirin-sensitive 
patients, meloxicam should not be administered to patients with this form of 
aspirin sensitivity and should be used with caution in patients with 
pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.6"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><a href="http://"></a><span class="Bold">Patients should be informed of the 
following information before initiating therapy with an NSAID and periodically 
during the course of ongoing therapy. Patients should also be encouraged to read 
the NSAID Medication Guide that accompanies each prescription dispensed.</span></p>
<ol>
<li>Meloxicam, like other NSAIDs, may cause serious CV side effects, such as MI 
or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious 
CV events can occur without warning symptoms, patients should be alert for the 
signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of 
speech, and should ask for medical advice when observing any indicative sign or 
symptoms. Patients should be apprised of the importance of this follow-up (see 
<span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID28">Cardiovascular Effects</a></span>). </li>
<li>Meloxicam, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious 
GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in 
hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the 
signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical 
advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, 
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the 
importance of this follow-up (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID35">Gastrointestinal (GI) Effects - Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, 
and Perforation</a></span>).</li>
<li>Meloxicam, like other NSAIDs, can cause serious skin side effects such as 
<span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and 
even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients 
should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or 
other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical 
advice when observing any indicative signs or symptoms. Patients should be 
advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and 
contact their physicians as soon as possible.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> 
or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of 
hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper 
quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms). If these occur, patients should 
be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., 
<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients 
should be instructed to seek immediate emergency help (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>).</li>
<li>In late pregnancy, as with other NSAIDs, meloxicam should be avoided because 
it will cause premature closure of the ductus arteriosus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.7"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning 
symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 
Patients on long-term treatment with NSAIDs should have their CBC and a 
chemistry profile checked periodically. If clinical signs and symptoms 
consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur 
(e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, 
meloxicam should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.8"></a><p></p>
<h2>Drug Interactions</h2>
<a href="http://"></a>ACE-inhibitors<p class="First"><a href="http://"></a>Reports suggest that NSAIDs may diminish the 
antihypertensive effect of ACE-inhibitors. This interaction should be given 
consideration in patients taking NSAIDs concomitantly with ACE inhibitors.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Aspirin<p><a href="http://"></a>When meloxicam is administered with aspirin (1000 g TID) to 
healthy volunteers, it tended to increase the AUC (10%) and C<span class="Sub">max</span> (24%) of meloxicam. The clinical significance of this 
interaction is not known; however, as with other NSAIDs concomitant 
administration of meloxicam and aspirin is not generally recommended because of 
the potential for increased adverse effects.</p>
<p>Concomitant administration of low-dose aspirin with meloxicam may result in 
an increased rate of GI ulceration or other complications, compared to use of 
meloxicam alone. Meloxicam is not a substitute for aspirin for cardiovascular 
prophylaxis.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Cholestyramine<p><a href="http://"></a>Pretreatment for four days with cholestyramine significantly 
increased the clearance of meloxicam by 50%. This resulted in a decrease in 
t<span class="Sub">1/2</span>, from 19.2 hours to 12.5 hours, and a 35% reduction 
in AUC. This suggests the existence of a recirculation pathway for meloxicam in 
the gastrointestinal tract. The clinical relevance of this interaction has not 
been established.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Cimetidine<p><a href="http://"></a>Concomitant administration of 200 mg cimetidine QID did not 
alter the single-dose pharmacokinetics of 30 mg meloxicam.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Digoxin<p><a href="http://"></a>Meloxicam 15 mg once daily for 7 days did not alter the 
plasma concentration profile of digoxin after β-acetyldigoxin administration for 
7 days at clinical doses. <span class="Italics">In vitro </span>testing found no 
protein binding drug interaction between digoxin and meloxicam.</p>
<p><span>Furosemide</span></p>
<p>Clinical studies, as well as post-marketing observations, have shown that 
NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal prostaglandin 
synthesis. Studies with furosemide agents and meloxicam have not demonstrated a 
reduction in natriuretic effect. Furosemide single and multiple dose 
pharmacodynamics and pharmacokinetics are not affected by multiple doses of 
meloxicam. Nevertheless, during concomitant therapy with meloxicam, patients 
should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>, <span class="Bold"><a href="#ID37">Renal 
Effects</a></span>), as well as to assure diuretic efficacy.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Lithium<p><a href="http://"></a>In a study conducted in healthy subjects, mean pre-dose 
lithium concentration and AUC were increased by 21% in subjects receiving 
lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as 
compared to subjects receiving lithium alone. These effects have been attributed 
to inhibition of renal prostaglandin synthesis by meloxicam. Patients on lithium 
treatment should be closely monitored for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> when 
meloxicam is introduced, adjusted, or withdrawn.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Methotrexate<p><a href="http://"></a>NSAIDs have been reported to competitively inhibit 
methotrexate accumulation in rabbit kidney slices. This may indicate that they 
could enhance the toxicity of methotrexate. Caution should be used when NSAIDs 
are administered concomitantly with methotrexate.</p>
<p>A study in 13 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) patients evaluated the effects of 
multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once 
weekly. Meloxicam did not have a significant effect on the pharmacokinetics of 
single doses of methotrexate.<span class="Italics">In vitro</span>, methotrexate 
did not displace meloxicam from its human serum binding sites.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Warfarin<p><a href="http://"></a>The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are 
synergistic, such that users of both drugs together have a risk of serious GI 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
<p>Anticoagulant activity should be monitored, particularly in the first few 
days after initiating or cha nging meloxicam therapy in patients receiving 
warfarin or similar agents, since these patients are at an increased risk of 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The effect of meloxicam on the anticoagulant effect of warfarin was 
studied in a group of healthy subjects receiving daily doses of warfarin that 
produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these 
subjects, meloxicam did not alter warfarin pharmacokinetics and the average 
anticoagulant effect of warfarin as determined by <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. However, one 
subject showed an increase in INR from 1.5 to 2.1. Caution should be used when 
administering meloxicam with warfarin since patients on warfarin may experience 
changes in INR and an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications when a new 
medication is introduced.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a href="http://"></a>No carcinogenic effect of meloxicam was observed in rats 
given oral doses up to 0.8 mg/kg/day (approximately 0.4-fold the human dose at 
15 mg/day for a 50 kg adult based on body surface area conversion) for 104 weeks 
or in mice given oral doses up to 8.0 mg/kg/day (approximately 2.2-fold the 
human dose, as noted above) for 99 weeks.</p>
<p>Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome 
aberration assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and an <span class="Italics">in vivo 
</span>micronucleus test in mouse bone marrow. </p>
<p>Meloxicam did not impair male and female fertility in rats at oral doses up 
to 9 and 5 mg/kg/day, respectively (4.9-fold and 2.5-fold the human dose, as 
noted above). However, an increased incidence of embryolethality at oral doses 
≥1 mg/kg/day (0.5-fold the human dose, as noted above) was observed in rats when 
dams were given meloxicam 2 weeks prior to mating and during early embryonic 
development. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.10"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><a href="http://"></a><span class="Bold">Teratogenic Effects: </span><span class="Italics">Pregnancy Category C.</span></p>
<p>Meloxicam caused an increased incidence of septal defect of the heart, a rare 
event, at an oral dose of 60 mg/kg/day (64.5-fold the human dose at 15 mg/day 
for a 50 kg adult based on body surface area conversion) and embryolethality at 
oral doses ≥5 mg/kg/day (5.4-fold the human dose, as noted above) when rabbits 
were treated throughout organogenesis. Meloxicam was not teratogenic in rats up 
to an oral dose of 4 mg/kg/day (approximately 2.2-fold the human dose, as noted 
above) throughout organogenesis. An increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> was 
observed when rats were given oral doses ≥1 mg/kg/day throughout organogenesis. 
Meloxicam crosses the placental barrier. There are no adequate and 
well-controlled studies in pregnant women. Meloxicam should be used during 
pregnancy only if the potential benefit justifies the potential risk to the 
fetus.</p>
<a href="http://"></a><a href="http://"></a><p><a href="http://"></a><span class="Italics">Nonteratogenic Effects</span></p>
<p>Because of the known effects of nonsteroidal antiinflammatory drugs on the 
fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy 
(particularly late pregnancy) should be avoided.</p>
<p>Meloxicam caused a reduction in birth index, live births, and neonatal 
survival at oral doses ≥0.125 mg/kg/day (approximately 0.07-fold the human dose 
at 15 mg/day for a 50 kg adult based on body surface area conversion) when rats 
were treated during the late gestation and lactation period. No studies have 
been conducted to evaluate the effect of meloxicam on the closure of the ductus 
arteriosus in humans; use of meloxicam during the third trimester of pregnancy 
should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.11"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First"><a href="http://"></a>Studies in rats with meloxicam, as with other drugs known to 
inhibit prostaglandin synthesis, showed an increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, 
prolonged delivery, and delayed parturition at oral dosages ≥1 mg/kg/day 
(approximately 0.5-fold the human dose at 15 mg/day for a 50 kg adult based on 
body surface area conversion), and decreased pup survival at an oral dose of 4 
mg/kg/day (approximately 2.1-fold the human dose, as noted above) throughout 
organogenesis. Similar findings were observed in rats receiving oral dosages 
≥0.125 mg/kg/day (approximately 0.07-fold the human dose, as noted above) during 
late gestation and the lactation period.</p>
<p>The effects of meloxicam on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk however, meloxicam 
was excreted in the milk of lactating rats at concentrations higher than those 
in plasma. Because many drugs are excreted in human milk and because of the 
potential for serious adverse reactions in nursing infants from meloxicam, a 
decision should be made whether to discontinue nursing or to discontinue the 
drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.13"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Use of this drug for a pediatric indication is protected by marketing 
exclusivity.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.14"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">As with any NSAID, caution should be exercised in treating the elderly (65 years 
and older).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<p class="First"><a href="http://"></a><span><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and Rheumatoid 
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></span></p>
<p>The meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients 
and 1012 RA patients treated with meloxicam 7.5 mg/day and 3,505 OA patients and 
1351 RA patients treated with meloxicam 15 mg/day. Meloxicam at these doses was 
administered to 661 patients for at least 6 months and to 312 patients for at 
least one year. Approximately 10,500 of these patients were treated in ten 
placebo and/or active-controlled <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> trials and 2363 of this patients 
were treated in ten placebo and/or active controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> 
trials. Gastrointestinal (GI) adverse events were the most frequently reported 
adverse events in all treatment groups across meloxicam trials. </p>
<p>A 12-week multicenter, double-blind, randomized trial was conducted in 
patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee or hip to compare the efficacy and 
safety of meloxicam with placebo and with an active control. Two 12-week 
multicenter, double-blind, randomized trials were conducted in patients with 
<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> to compare the efficacy and safety of meloxicam with 
placebo. </p>
<p>Table 2a depicts adverse events that occurred in ≥ 2% of the meloxicam 
treatment groups in a 12-week placebo and active-controlled <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> 
trial.</p>
<p>Table 2b depicts adverse events that occurred in ≥2% of the meloxicam 
treatment groups in two 12-week placebo controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> trials.</p>
<a name="i1af256f1-dee2-4ece-8329-0559c1fd8706"></a><table width="100%">
<caption><span>Table 2a Adverse Events (%) Occurring in ≥ 2% of Meloxicam Patients in a 12-Week <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Placebo and Active-Controlled Trial</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><span class="Bold">Placebo<br><br></span></td>
<td><span class="Bold">MELOXICAM<br>7.5 mg daily<br></span></td>
<td><span class="Bold">MELOXICAM<br>15 mg daily<br></span></td>
<td><span class="Bold">Diclofenac<br>100 mg daily<br></span></td>
</tr>
<tr>
<td>
<span class="Bold">No. of Patients</span><br>
</td>
<td>
<span class="Bold">157</span><br>
</td>
<td>
<span class="Bold">154</span><br>
</td>
<td>
<span class="Bold">156</span><br>
</td>
<td>
<span class="Bold">153</span><br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Gastrointestinal</span><br>     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>     <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td>17.2<br>2.5<br>3.8<br>4.5<br>4.5<br>3.2<br>
</td>
<td>20.1<br>1.9<br>7.8<br>4.5<br>3.2<br>3.9<br>
</td>
<td>17.3<br>2.6<br>3.2<br>4.5<br>3.2<br>3.8<br>
</td>
<td>28.1<br>1.3<br>9.2<br>6.5<br>3.9<br>7.2<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Body as a Whole<br>     </span><span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> Household<br>     <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><span class="Sup">1</span><br>     <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span><br>     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-Like Symptoms<br>
</td>
<td>
<br>1.9<br>2.5<br>0.6<br>5.1<br>
</td>
<td>
<br>4.5<br>1.9<br>2.6<br>4.5<br>
</td>
<td>
<br>3.2<br>4.5<br>0.0<br>5.8<br>
</td>
<td>
<br>2.6<br>3.3<br>1.3<br>2.6<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Central and Peripheral Nervous System<br>     </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td>
<br>3.2<br>10.2<br>
</td>
<td>
<br>2.6<br>7.8<br>
</td>
<td>
<br>3.8<br>8.3<br>
</td>
<td>
<br>2.0<br>5.9<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Respiratory<br>     </span><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br>     <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span><br>
</td>
<td>
<br>1.3<br>1.9<br>
</td>
<td>
<br>0.6<br>3.2<br>
</td>
<td>
<br>3.2<br>1.9<br>
</td>
<td>
<br>1.3<br>3.3<br>
</td>
</tr>
<tr class="Last">
<td>
<span class="Bold">Skin<br>     </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">2</span>
</td>
<td>
<br>2.5<br>
</td>
<td>
<br>2.6<br>
</td>
<td>
<br>0.6<br>
</td>
<td>
<br>2.0<br>
</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>  WHO preferred terms <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">edema dependent</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema legs</span> combined 
<br><span class="Sup">2</span>  WHO preferred terms <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular combined<br><br><br><a name="i1a3e2fb0-4ed1-4605-891e-5397a2382b4d"></a><table width="100%">
<caption><span>Table 2b Adverse Events (%) Occurring in ≥ 2% of Meloxicam
Patients in two 12-Week <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> Placebo Controlled Trials</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><span class="Bold">Placebo<br><br></span></td>
<td><span class="Bold">MELOXICAM<br>
7.5 mg daily<br></span></td>
<td><span class="Bold">MELOXICAM<br>
15 mg daily<br></span></td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold">No. of Patients</span><br>
</td>
<td>
<span class="Bold">469</span><br>
</td>
<td>
<span class="Bold">481</span><br>
</td>
<td>
<span class="Bold">477</span><br>
</td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span><br>
     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> NOS<span class="Sup">2</span><br>
     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> NOS<span class="Sup">2</span><br>
     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> signs and symptoms<span class="Sup">1</span><br>
     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><span class="Sup">2</span><br>
</td>
<td>14.1<br>0.6<br>5.1<br>3.8<br>2.6<br>
</td>
<td>18.9<br>2.9<br>4.8<br>5.8<br>3.3<br>
</td>
<td>16.8<br>2.3<br>3.4<br>4.0<br>3.8<br>
</td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold">General disorders and administration site conditions<br>     </span><span class="product-label-link" type="condition" conceptid="4153160" conceptname="Influenza-like symptoms">Influenza like illness</span><span class="Sup">2</span><span class="Bold"><span class="Sup"></span></span><span class="Sup"></span><br>
</td>
<td>
<br>2.1<br>
</td>
<td>
<br>2.9<br>
</td>
<td>
<br>2.3<br>
</td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span><br>     </span><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span>-<br>     Pathogen class unspecified<span class="Sup">1</span><br>
</td>
<td>
<br>4.1<br><br>
</td>
<td>
<br>7.0<br><br>
</td>
<td>
<br>6.5<br><br>
</td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span><br>     </span>Joint related signs and symptoms<span class="Sup">1</span><br>     Musculoskeletal and connective tissue<br>     signs and symptoms NEC<span class="Sup">1</span><br>
</td>
<td>
<br>1.9<br>3.8<br><br>
</td>
<td>
<br>1.5<br>1.7<br><br>
</td>
<td>
<br>2.3<br>2.9<br><br>
</td>
<td><br></td>
</tr>
<tr class="Last">
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span><br>
     </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> NOS<span class="Sup">2</span><br>     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excl <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)<span class="Sup">2</span><br><span class="Bold">Skin and subcutaneous tissue disorders<br>     </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> NOS<span class="Sup">2</span><br>
</td>
<td>
<br>6.4<br>3.0<br><br>1.7<br>
</td>
<td>
<br>6.4<br>2.3<br><br>1.0<br>
</td>
<td>
<br>5.5<br>0.4<br><br>2.1<br>
</td>
<td><br></td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>  MedDRA high level term (preferred terms): dyspeptic signs and symptoms 
(<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia aggravated</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>), 
<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>-pathogen unspecified (<span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span> NOS, 
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> NOS, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> NOS), joint related signs and symptoms (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, 
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia aggravated</span>, <span class="product-label-link" type="condition" conceptid="4100499" conceptname="Joint crepitus">joint crepitation</span>, <span class="product-label-link" type="condition" conceptid="72407" conceptname="Effusion of joint of shoulder region">joint effusion</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>), and 
musculoskeletal and connective tissue signs and symptoms NEC (<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, back 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain aggravated</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>) <br><span class="Sup">2</span>  MedDRA preferred term: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> NOS, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> NOS, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> like 
illness, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> NOS, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (excl <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> NOS <br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First">The adverse events that occurred with meloxicam in ≥ 2% of patients treated 
short-term (4-6 weeks) and long-term (6 months) in active-controlled 
<span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> trials are presented in Table 3.</p>
<a name="i3be740d9-1637-4afa-8bf5-6d3265c1b038"></a><table width="100%">
<caption><span>Table 3 Adverse Events (%) Occurring in ≥ 2% of Meloxicam Patients in 4 to 6 Weeks and 6 Month Active-Controlled <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Trials</span></caption>
<thead><tr class="First Last">
<th><br></th>
<th> 4-6 Weeks Controlled</th>
<th>Trials<br>
</th>
<th> 6 Month<br>
</th>
<th> Controlled Trials<br>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td><br></td>
<td><span class="Bold">MELOXICAM<br>7.5 mg daily</span></td>
<td><span class="Bold">MELOXICAM       <br>15 mg daily</span></td>
<td><span class="Bold">MELOXICAM<br>7.5 mg daily</span></td>
<td><span class="Bold">MELOXICAM<br>15 mg daily</span></td>
</tr>
<tr>
<td><span class="Bold">No. of Patients</span></td>
<td><span class="Bold">8955</span></td>
<td><span class="Bold">256</span></td>
<td><span class="Bold">169</span></td>
<td><span class="Bold">306</span></td>
</tr>
<tr>
<td>
<span class="Bold">Gastrointestinal<br>     </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br>     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>     <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td>11.8<br>2.7<br>0.8<br>1.9<br>3.8<br>0.5<br>2.4<br>0.6<br>
</td>
<td>18.0<br>2.3<br>1.2<br>2.7<br>7.4<br>0.4<br>4.7<br>0.8<br>
</td>
<td>26.6<br>4.7<br>1.8<br>5.9<br>8.9<br>3.0<br>4.7<br>1.8<br>
</td>
<td>24.2<br>2.9<br>2.6<br>2.6<br>9.5<br>2.6<br>7.2<br>2.6<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Body as a Whole<br>     </span><span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> Household<br>     <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><span class="Sup">1</span><br>     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td>
<br>0.0<br>0.6<br>0.90<br>
</td>
<td>
<br>0.0<br>2.0<br>2.0<br>
</td>
<td>
<br>0.6<br>2.4<br>3.6<br>
</td>
<td>
<br>2.9<br>1.6<br>5.2<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Central and Peripheral Nervous System<br>     </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td>
<br>1.1<br>2.4<br>
</td>
<td>
<br>1.6<br>2.7<br>
</td>
<td>
<br>2.4<br>3.6<br>
</td>
<td>
<br>2.6<br>2.6<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Hematologic<br>     </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td>
<br>0.1<br>
</td>
<td>
<br>0.0<br>
</td>
<td>
<br>4.1<br>
</td>
<td>
<br>2.9<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Musculoskeletal<br>     </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span><br>     <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span><br>
</td>
<td>
<br>0.5<br>0.5<br>
</td>
<td>
<br>0.0<br>0.4<br>
</td>
<td>
<br>5.3<br>3.0<br>
</td>
<td>
<br>1.3<br>0.7<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Psychiatric<br>     </span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td>
<br>0.4<br>
</td>
<td>
<br>0.0<br>
</td>
<td>
<br>3.6<br>
</td>
<td>
<br>1.6<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Respiratory<br>     </span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span><br>     <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span><br>
</td>
<td>
<br>0.2<br>0.2<br>
</td>
<td>
<br>0.8<br>0.0<br>
</td>
<td>
<br>2.4<br>8.3<br>
</td>
<td>
<br>1.0<br>7.5<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Skin<br>     </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span><br>     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">2</span><br>
</td>
<td>
<br>0.4<br>0.3<br>
</td>
<td>
<br>1.2<br>1.2<br>
</td>
<td>
<br>2.4<br>3.0<br>
</td>
<td>
<br>0.0<br>1.3<br>
</td>
</tr>
<tr class="Last">
<td>
<span class="Bold">Urinary<br>     </span>Micturition Frequency<br>     <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span><br>
</td>
<td>
<br>0.1<br>0.3<br>
</td>
<td>
<br>0.4<br>0.4<br>
</td>
<td>
<br>2.4<br>4.7<br>
</td>
<td>
<br>1.3<br>6.9<br>
</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>  WHO preferred terms <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">edema dependent</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema legs</span> combined<br><span class="Sup">2</span>  WHO preferred terms <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular combined<br><br><p><a href="http://"></a>Higher doses of meloxicam (22.5 mg and greater) have been 
associated with an increased risk of serious GI events; therefore the daily dose 
of meloxicam should not exceed 15 mg. </p>
<p>The following is a list of adverse drug reactions occurring in less than 2% of 
patients receiving meloxicam in clinical trials involving approximately 16,200 
patients. Adverse reactions reported only in worldwide post-marketing experience 
or the literature are shown in italics.</p>
<a href="http://"></a><a name="i7187d04a-36f0-4f25-86b2-6d2938b90260"></a><table width="100%">
<col width="36%">
<col width="64%">
<thead><tr class="First Last">
<td><p class="First"><span class="Bold">Body as a Whole  </span></p></td>
<td>allergic reaction, <span class="Italics">anaphylactoid reactions including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>,</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, hot flushes, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, weight decrease, weight increase 
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Cardiovascular  </span></p></td>
<td>angina pectoris, cardiac failure, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>myocardial <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> 
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Central and Peripheral Nervous System  
</span></p></td>
<td><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Gastrointestinal  </span></p></td>
<td><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, dry mouth, duodenal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>gastric <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, gastroesophageal reflux, 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>gastrointestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, hemorrhagic 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>duodenal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, hemorrhagic gastric <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, intestinal 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>perforation, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>perforated duodenal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, perforated gastric <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>,  
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>stomatitis ulcerative </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Heart Rate and Rhythm  </span></p></td>
<td><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hematologic </span></p></td>
<td>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>,</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, thrombocytopenia   
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Liver and Biliary System  </span></p></td>
<td>ALT increased, AST increased, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, GGT  </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>increased, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, liver failure </span>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Metabolic and Nutritional  </span></p></td>
<td>dehydration  </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Psychiatric </span></p></td>
<td>Abnormal dreaming, <span class="Italics">alterations in mood (such as mood  </span>
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>
<span class="Italics">elevation),</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, appetite increased, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> 
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory  </span></p></td>
<td><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, dyspnea  
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Skin and Appendages  </span></p></td>
<td><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, bullous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></span>
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>
<span class="Italics">multiforme,</span> photosensitivity reaction, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td><p class="First"><span class="Italics">exfoliative </span></p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, Stevens-Johnson syndrome,</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>increased, </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>
<span class="Italics">toxic epidermal necrolysis,</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Special Senses  </span></p></td>
<td>abnormal vision, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, taste perversion,  </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> </td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Urinary System  </span></p></td>
<td>
<span class="Italics">acute urinary retention,</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, BUN  </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>increased, </td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>creatinine increased, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="Italics">interstitial</span>
</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Bold"></span></p>
<br>
</td>
<td>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>,</span> renal failure </td>
</tr>
</tbody>
</table>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a href="http://"></a>There is limited experience with meloxicam <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Four 
cases have taken 6 to 11 times the highest recommended dose; all recovered. 
Cholestyramine is known to accelerate the clearance of meloxicam.</p>
<p>Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally 
reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. Severe 
<span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may result in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, hepatic dysfunction, 
<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, and cardiac 
arrest. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of 
NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Patients should be managed with symptomatic and supportive care following an 
NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, gastric lavage followed by activated 
charcoal is recommended. Gastric lavage performed more than one hour after 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has little benefit in the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Administration of 
activated charcoal is recommended for patients who present 1-2 hours after 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. For substantial <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or severely symptomatic patients, activated 
charcoal may be administered repeatedly. Accelerated removal of meloxicam by 4 
gm oral doses of cholestyramine given three times a day was demonstrated in a 
clinical trial. Administration of cholestyramine may be useful following an 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine, hemodialysis, or 
hemoperfusion may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First"><a href="http://"></a>Carefully consider the potential benefits and risks of 
meloxicam and other treatment options before deciding to use meloxicam. Use the 
lowest effective dose for the shortest duration consistent with individual 
patient treatment goals (see <span class="Bold"><a href="#ID27">WARNINGS</a></span>).</p>
<p>After observing the response to initial therapy with meloxicam, the dose 
should be adjusted to suit an individual patient's needs.</p>
<p>For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> the recommended 
starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some 
patients may receive additional benefit by increasing the dose to 15 mg once 
daily. For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, the 
recommended starting and maintenance oral dose of meloxicam is 7.5 mg once 
daily. Some patients may receive additional benefit by increasing the dose to 15 
mg once daily.</p>
<p>The maximum recommended daily oral dose of meloxicam is 15 mg.</p>
<p>Meloxicam may be taken without regard to timing of meals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a href="#section-"></a>Meloxicam Tablets USP are available as light yellow, round, 
flat, uncoated tablets containing meloxicam 7.5 mg or as light yellow, oblong, 
biconvex, uncoated tablets containing meloxicam 15 mg. The 7.5 mg tablet is 
impressed with letter U and L on one side and tablet code 7.5 on the other side. 
The 15 mg tablet is impressed with letter U and L on one side and tablet code 15 
on the other side.</p>
<p><br></p>
<p>Meloxicam Tablets USP 7.5 mg are available as follows:</p>
<a name="i7ab87690-bf08-47f0-8f19-093f9433e013"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>NDC 54868-5650-4<br>NDC 54868-5650-6<br>
</td>
<td>Bottles of 10<br>Bottles of 15<br>
</td>
</tr>
<tr>
<td>NDC 54868-5650-5<br>
</td>
<td>Bottles of 20<br>
</td>
</tr>
<tr>
<td>NDC 54868-5650-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
<tr>
<td>NDC 54868-5650-1<br>
</td>
<td>Bottles of 60<br>
</td>
</tr>
<tr>
<td>NDC 54868-5650-3<br>
</td>
<td>Bottles of 90<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-5650-2<br>
</td>
<td>Bottles of 100<br>
</td>
</tr>
</tbody></table>
<br><p>Meloxicam Tablets USP 15 mg are available as follows:</p>
<a name="ia58de9b6-126f-4a12-8d05-3d593df6b241"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>NDC 54868-5651-4<br>NDC 54868-5651-0<br>
</td>
<td>Bottles of 15<br>Bottles of 30<br>
</td>
</tr>
<tr>
<td>NDC 54868-5651-2<br>
</td>
<td>Bottles of 60<br>
</td>
</tr>
<tr>
<td>NDC 54868-5651-3<br>
</td>
<td>Bottles of 90<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-5651-1<br>
</td>
<td>Bottles of 100<br>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<h1>STORAGE AND HANDLING</h1>
<p class="First"><a href="http://"></a><span class="Bold">Store at Controlled Room Temperature 
20°-25°C (68°-77°F) [See USP]</span></p>
<p>Please address medical inquiries to medical@unichemindia.com</p>
<p><span class="Bold">Keep meloxicam tablets in a dry place</span></p>
<p>Dispense tablets in a tight container.</p>
<p>Keep this and all medications out of the reach of children.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><a href="http://"></a>Manufactured by:</p>
<p><span class="Bold">UNICHEM LABORATORIES LTD.</span></p>
<p>Pilerne Ind. Estate, </p>
<p>Pilerne, Bardez, Goa 403511, India</p>
<p>Marketed by :</p>
<p><img alt="image of Unichem logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe8480c4-b176-45ae-b4d6-fa59912fe286&amp;name=Unichem%20logo.jpg"></p>
<p><a href="http://"></a>Rochelle Park, NJ 07662</p>
<p>PSEUSA043-00</p>
<p>Revised: January 2009</p>
<br><p><br></p>
<p>Relabeling and Repackaging by:<br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-14"></a><p></p>
<p class="First"><a href="http://"></a><span class="Bold">Meloxicam Tablets USP 7.5 mg and 15 
mg</span></p>
<p><span class="Bold">Medication Guide for Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs)</span></p>
<p><span class="Underline">(See the end of this Medication Guide for a list of 
prescription NSAID medicines).</span></p>
<p><span class="Bold">What is the most important information I should know about 
medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This chance increases:</span></p>
<ul>
<li>with longer use of NSAID medicines </li>
<li>in people who have heart disease </li>
</ul>
<p><a href="http://"></a><span class="Bold">NSAID medicines should never be used right 
before or after a heart surgery called a "coronary artery bypass graft 
(CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach 
and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul>
<li>can happen without warning symptoms </li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </li>
</ul>
<p><a href="http://"></a><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<ul>
<li>taking medicines called "corticosteroids" and "anticoagulants" </li>
<li>longer use </li>
<li>smoking </li>
<li>drinking alcohol </li>
<li>older age </li>
<li>having poor health </li>
</ul>
<p><a href="http://"></a><span class="Bold">NSAID medicines should only be 
used:</span></p>
<ul>
<li>exactly as prescribed </li>
<li>at the lowest dose possible for your treatment </li>
<li>for the shortest time needed </li>
</ul>
<p><a href="http://"></a><span class="Bold">What are Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat 
(<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </li>
</ul>
<p><a href="http://"></a><span class="Bold">Who should not take a Non-Steroidal 
Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin 
or any other NSAID medicine </li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery </li>
</ul>
<p><a href="http://"></a><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions </li>
<li>about all of the medicines you take. NSAIDs and some other medicines can 
interact with each other and cause serious side effects. <span class="Bold">Keep a 
list of your medicines to show to your healthcare provider and pharmacist 
</span>
</li>
<li>if you are pregnant. NSAID medicines should not be used by pregnant women 
late in their pregnancy </li>
<li>if you are breastfeeding. Talk to your doctor </li>
</ul>
<a href="http://"></a><a name="i1beed1e6-3a8f-4083-8843-ce848747978c"></a><table width="100%">
<col width="100%">
<thead><tr class="First Last"><td><p class="First"><span class="Bold">What are the possible side effects of 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p></td></tr></thead>
<tbody>
<tr class="First"><td>
<p class="First"><span class="Bold"></span></p>
<br>
</td></tr>
<tr><td><p class="First"><span class="Bold">Serious side effects include: 
</span></p></td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </td></tr>
<tr><td>     • high blood pressure </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body 
<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) </td></tr>
<tr><td>     • kidney problems including 
<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the 
stomach and intestine </td></tr>
<tr><td>     • low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) 
</td></tr>
<tr><td>     • life-threatening skin 
reactions </td></tr>
<tr><td>     • life-threatening allergic 
reactions </td></tr>
<tr><td>     • liver problems including liver 
failure </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who 
have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> </td></tr>
<tr><td><br></td></tr>
<tr><td><p class="First"><span class="Bold">Other side effects include: 
</span></p></td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </td></tr>
<tr><td>     • gas </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </td></tr>
<tr><td>     • <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </td></tr>
<tr class="Last"><td>     • <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 
</td></tr>
</tbody>
</table>
<p><a href="http://"></a><span class="Bold">Get emergency help right away if you have 
any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing </li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body </li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the face or throat </li>
</ul>
<p><a href="http://"></a><span class="Bold">Stop your NSAID medicine and call your 
healthcare provider right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
<li>more tired or weaker than usual </li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </li>
<li>your skin or eyes look yellow </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </li>
<li>flu-like symptoms </li>
<li>vomit blood </li>
<li>there is blood in your bowel movement or it is black and sticky like tar 
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet </li>
</ul>
<p><a href="http://"></a>These are not all the side effects with NSAID medicines. 
Talk to your healthcare provider or pharmacist for more information about NSAID 
medicines.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You 
may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p>Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</p>
<p>Aspirin is an NSAID medicine but it does not increase the chance of a heart 
attack. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. 
Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines. Some of these NSAID 
medicines are sold in lower doses without a prescription (over-the-counter). 
Talk to your healthcare provider before using over-the-counter NSAIDs for more 
than 10 days.</p>
<p><span>NSAID medicines that need a prescription</span></p>
<a href="http://"></a><a name="i8cb11180-203d-4453-8109-b6badb4599a3"></a><table width="100%">
<col width="30%">
<col width="70%">
<thead><tr class="First Last">
<td><p class="First"><span class="Bold">Generic Name </span></p></td>
<td><p class="First"><span class="Bold">Tradename  </span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td>Celecoxib  </td>
<td>Celebrex  </td>
</tr>
<tr>
<td>Diclofenac  </td>
<td>Cataflam, Voltaren, Arthrotec (combined with misoprostol) </td>
</tr>
<tr>
<td>Diflunisal </td>
<td>Dolobid  </td>
</tr>
<tr>
<td>Etodolac </td>
<td>Lodine, Lodine XL 
</td>
</tr>
<tr>
<td>Fenoprofen </td>
<td>Nalfon, Nalfon 200 
</td>
</tr>
<tr>
<td>Flurbiprofen </td>
<td>Ansaid </td>
</tr>
<tr>
<td>Ibuprofen  </td>
<td>Motrin, Tab-Profen, Vicoprofen<span class="Sup">*</span> (combined with 
</td>
</tr>
<tr>
<td><br></td>
<td>hydrocodone), Combunox (combined with oxycodone) </td>
</tr>
<tr>
<td>Indomethacin </td>
<td>Indocin, Indocin SR, Indo-Lemmon, Indomethegan  </td>
</tr>
<tr>
<td>Ketoprofen </td>
<td>Oruvail  </td>
</tr>
<tr>
<td>Ketorolac </td>
<td>Toradol  </td>
</tr>
<tr>
<td>Mefenamic Acid </td>
<td>Ponstel  </td>
</tr>
<tr>
<td>Meloxicam </td>
<td>Mobic  </td>
</tr>
<tr>
<td>Nabumetone </td>
<td>Relafen  </td>
</tr>
<tr>
<td>Naproxen </td>
<td>Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan,  </td>
</tr>
<tr>
<td><br></td>
<td>PREVACID NapraPAC (copackaged with lansoprazole) </td>
</tr>
<tr>
<td>Oxaprozin </td>
<td>Daypro </td>
</tr>
<tr>
<td>Piroxicam </td>
<td>Feldene </td>
</tr>
<tr>
<td>Sulindac </td>
<td>Clinoril </td>
</tr>
<tr class="Last">
<td>Tolmetin </td>
<td>Tolectin, Tolectin DS, Tolectin 600  </td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a><p><a href="http://"></a>*  Vicoprofen contains the same dose of ibuprofen as over-the counter ( OTC ) 
NSAIDS, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID 
label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> 
or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>Manufactured by:</p>
<p><span class="Bold">UNICHEM LABORATORIES LTD.</span></p>
<p>Pilerne Ind. Estate,</p>
<p>Pilerne, Bardez, Goa 403511, India</p>
<p>Marketed by:</p>
<p><img alt="image of Unichem logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe8480c4-b176-45ae-b4d6-fa59912fe286&amp;name=Unichem%20logo.jpg"></p>
<p><a href="http://"></a>Rochelle Park, NJ 07662</p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food 
and Drug Administration</span></p>
<p>PSEUSA044A-00</p>
<p>Revised: January 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Meloxicam Tablets USP <br></p>
<p>7.5 mg</p>
<div class="Figure"><img alt="image of 7.5 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe8480c4-b176-45ae-b4d6-fa59912fe286&amp;name=package%20label%2001.jpg"></div>
<p><br></p>
<p>Meloxicam Tablets USP <br></p>
<p>15 mg</p>
<p><img alt="image of 15 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe8480c4-b176-45ae-b4d6-fa59912fe286&amp;name=package%20label%2002.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MELOXICAM 		
					</strong><br><span class="contentTableReg">meloxicam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5650(NDC:29300-124)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MELOXICAM</strong> (MELOXICAM) </td>
<td class="formItem">MELOXICAM</td>
<td class="formItem">7.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (Light Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">U;L;7;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5650-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5650-1</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5650-2</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5650-3</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-5650-4</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-5650-5</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:54868-5650-6</td>
<td class="formItem">15  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077927</td>
<td class="formItem">08/07/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MELOXICAM 		
					</strong><br><span class="contentTableReg">meloxicam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5651(NDC:29300-125)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MELOXICAM</strong> (MELOXICAM) </td>
<td class="formItem">MELOXICAM</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (Light Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">U;L;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5651-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5651-1</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5651-2</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5651-3</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-5651-4</td>
<td class="formItem">15  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077927</td>
<td class="formItem">08/07/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5944937d-4840-4562-a5ae-30825414ce0b</div>
<div>Set id: fe8480c4-b176-45ae-b4d6-fa59912fe286</div>
<div>Version: 4</div>
<div>Effective Time: 20100722</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
